MCID: EWN003
MIFTS: 72

Ewing Sarcoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Eye diseases, Bone diseases

Aliases & Classifications for Ewing Sarcoma

MalaCards integrated aliases for Ewing Sarcoma:

Name: Ewing Sarcoma 53 12 49 24 55 71 13 14
Neuroepithelioma 53 72 49 55 51 69
Ewing's Sarcoma 72 49 24 36 28
Ewing's Tumor 12 49 24 71
Ewings Sarcoma 12 51 69
Eye Diseases 51 40 41
Localized Peripheral Primitive Neuroectodermal Tumor 12 69
Ewings Sarcoma-Primitive Neuroectodermal Tumor 12 69
Peripheral Primitive Neuroectodermal Tumor 12 55
Peripheral Neuroepithelioma 71 51
Askin Tumor 71 41
Eye Disease 12 14
Ewing Tumor 49 24
Es 53 71
Localized Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Extraosseous Ewings Sarcoma-Primitive Neuroepithelial Tumor 69
Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Neuroectodermal Tumors, Primitive, Peripheral 41
Neuroectodermal Tumor, Primitive 69
Pnet of Thoracopulmonary Region 12
Primitive Neuroectodermal Tumor 71
Ewing's Family Localized Tumor 12
Ewing Sarcoma Family of Tumors 71
Neuroepithelioma, Peripheral 69
Localized Ewing's Sarcoma 12
Tumor of the Ewing Family 24
Extraosseous Ewing Tumor 71
Localized Ewing Sarcoma 12
Localized Ewing's Tumor 12
Ewing Family of Tumors 24
Pnet of the Chest Wall 71
Abnormality of the Eye 28
Sarcoma, Ewing's 49
Peripheral Pnet 55
Disorder of Eye 69
Sarcoma, Ewing 41
Askin's Tumor 69
Ppnet 55
Pnet 71
Esft 71
Pne 71

Characteristics:

Orphanet epidemiological data:

55
ewing sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;
neuroepithelioma
Inheritance: Not applicable; Age of onset: Childhood;

HPO:

31
ewing sarcoma:
Inheritance somatic mutation


Classifications:



Summaries for Ewing Sarcoma

NIH Rare Diseases : 49 Ewing sarcoma is a malignant (cancerous) bone tumor that affects children. It can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. The tumor may arise anywhere in the body, usually in the long bones of the arms and legs, the pelvis, or the chest. It may also develop in the skull or the flat bones of the trunk. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Fever may also be present. The tumor often spreads (metastasis) to the lungs and other bones. The cause of Ewing sarcoma is unknown. Most cases are thought to occur randomly and many involved a reciprocal translocation between chromosomes 11 and 22. Treatment depends upon a number of factors, but may include chemotherapy, radiation and/or surgical interventions. Last updated: 2/13/2016

MalaCards based summary : Ewing Sarcoma, also known as neuroepithelioma, is related to extraskeletal ewing sarcoma and bone ewing's sarcoma, and has symptoms including ewing's sarcoma, fever and visual disturbance. An important gene associated with Ewing Sarcoma is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Afinitor and Erbitux have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

OMIM : 53 The Ewing sarcoma family of tumors (primitive neuroectodermal tumors; PNET) comprise morphologically heterogeneous tumors that are characterized by nonrandom chromosomal translocations involving the EWS gene on chromosome 22q12 and one of several members of the ETS family of transcription factors. The tumors include Ewing sarcoma, peripheral neuroepithelioma, and Askin tumor. In approximately 90% of cases of ESFT, the FLI1 gene (193067) on chromosome 11 is the fusion partner of EWS; in approximately 10%, the EWS fusion partner is the ERG gene (165080) on chromosome 22. Many other ETS family members have been identified as fusion partners of EWS, but these cases are rare (Khoury, 2005). (612219)

UniProtKB/Swiss-Prot : 71 Ewing sarcoma: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

MedlinePlus : 40 Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pinkeye Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute

Genetics Home Reference : 24 Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

Disease Ontology : 12 A bone cancer that has_material_basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm.

Wikipedia : 72 Ewing sarcoma or Ewing\'s sarcoma (/ˈjuːɪŋ/) is a malignant small, round, blue cell tumor. It is a rare... more...

Related Diseases for Ewing Sarcoma

Diseases related to Ewing Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 extraskeletal ewing sarcoma 35.1 CD99 ENO2 ERG EWSR1 FLI1 FUS
2 bone ewing's sarcoma 33.6 CD99 ENO2 EWSR1 PTPRC WT1
3 extraosseous ewing's sarcoma 33.4 CD99 ENO2 ETV4 EWSR1
4 ewing's family of tumors 33.2 EWSR1 FLI1 KIT
5 sarcoma 33.1 ERG EWSR1 FLI1 FUS KIT
6 askin's tumor 32.8 ENO2 EWSR1
7 spiradenoma 32.4 ABCC6 IMPG2 RDH12
8 desmoplastic small round cell tumor 31.7 CD99 ENO2 EWSR1 FLI1 PTPRC WT1
9 rhabdomyosarcoma 31.6 ENO2 EWSR1 IGF1R PTPRC
10 olfactory neuroblastoma 31.3 ENO2 EWSR1 PTPRC
11 leukemia, acute myeloid 31.3 DNTT KIT NCAM1 PTPRC WT1
12 rhabdomyosarcoma 2 31.2 ENO2 IGF1R WT1
13 clear cell sarcoma 31.1 ENO2 EWSR1 FUS KIT WT1
14 lymphoblastic lymphoma 31.1 DNTT FGFR1 FLI1 PTPRC
15 gastrointestinal stromal tumor 31.1 ENO2 ETV1 KIT PDGFRB
16 merkel cell carcinoma 31.0 ENO2 KIT NCAM1
17 fish-eye disease 12.3
18 aland island eye disease 12.3
19 bornholm eye disease 12.2
20 extraosseous ewings sarcoma-primitive neuroepithelial tumor 12.1
21 soft tissue peripheral neuroepithelioma 12.0
22 bone peripheral neuroepithelioma 12.0
23 dissociative seizures 11.7
24 pineoblastoma 11.5
25 supratentorial primitive neuroectodermal tumor 11.1
26 kidney rhabdoid cancer 11.1 CD99 ENO2 EWSR1 PTPRC WT1
27 rhabdoid cancer 11.1 ENO2 EWSR1 IGF1R PTPRC WT1
28 connective tissue cancer 11.1 CD99 ENO2 EWSR1 FUS KIT
29 teratoma 11.0 CD99 ENO2 KIT POU5F1
30 cell type cancer 11.0 ENO2 EWSR1 KIT POU5F1
31 chronic eosinophilic leukemia 11.0 FGFR1 KIT PDGFRB WT1
32 muscle cancer 11.0 ENO2 EWSR1 KIT WT1
33 histiocytoma 11.0 EWSR1 FUS KIT PTPRC
34 chondrosarcoma, extraskeletal myxoid 11.0 ENO2 EWSR1 FUS WT1
35 heart sarcoma 11.0 ENO2 KIT PDGFRB WT1
36 endometrial small cell carcinoma 11.0 ENO2 KIT NCAM1 PTPRC
37 malignant mesenchymoma 11.0 EWSR1 KIT NCAM1 WT1
38 leiomyosarcoma 11.0 ENO2 KIT PDGFRB WT1
39 small cell carcinoma 11.0 ENO2 KIT NCAM1 PTPRC
40 cauda equina neoplasm 11.0 ENO2 EWSR1 WT1
41 testicular infarct 11.0 KIT POU5F1 PTPRC
42 extraosseous chondrosarcoma 11.0 ENO2 EWSR1 FUS
43 myeloid sarcoma 11.0 DNTT KIT NCAM1 PTPRC
44 conventional fibrosarcoma 11.0 ENO2 KIT PTPRC
45 orbital cancer 11.0 ENO2 EWSR1 NCAM1
46 epidural neoplasm 11.0 CD99 DNTT PTPRC
47 hypereosinophilic syndrome, idiopathic 11.0 KIT PDGFRB WT1
48 cutaneous ganglioneuroma 11.0 ENO2 KIT NCAM1
49 macular degeneration, age-related, 1 11.0
50 8p11 myeloproliferative syndrome 11.0 FGFR1 KIT PDGFRB

Graphical network of the top 20 diseases related to Ewing Sarcoma:



Diseases related to Ewing Sarcoma

Symptoms & Phenotypes for Ewing Sarcoma

Clinical features from OMIM:

612219

Human phenotypes related to Ewing Sarcoma:

31
# Description HPO Frequency HPO Source Accession
1 ewing's sarcoma 31 HP:0012254

UMLS symptoms related to Ewing Sarcoma:


fever, visual disturbance, lid retraction, pathological conditions, signs and symptoms, redness or discharge of eye, pain in or around eye, eye manifestations

GenomeRNAi Phenotypes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.87 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 EWSR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.87 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.87 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.87 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.87 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.87 IMPG2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.87 KIT WT1 EWSR1 IMPG2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.87 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.87 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 IMPG2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.87 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.87 IMPG2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.87 EWSR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.87 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.87 KIT WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.87 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.87 KIT EWSR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.87 EWSR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.87 EWSR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 WT1 KIT
27 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.87 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.87 KIT EWSR1
29 Decreased substrate adherent cell growth GR00193-A-1 9.43 IGF1R KIT
30 Decreased substrate adherent cell growth GR00193-A-2 9.43 KIT
31 Decreased substrate adherent cell growth GR00193-A-4 9.43 FGFR1 IGF1R KIT

MGI Mouse Phenotypes related to Ewing Sarcoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ENO2 ERG ETV1 FGFR1 FLI1 IGF1R
2 endocrine/exocrine gland MP:0005379 10.07 ERG ETV4 FGFR1 FLI1 IGF1R KIT
3 embryo MP:0005380 10.06 ERG ETV4 FGFR1 FLI1 IGF1R KIT
4 nervous system MP:0003631 9.97 ENO2 ERG ETV1 ETV4 FGFR1 FLI1
5 muscle MP:0005369 9.92 WT1 IGF1R KIT PDGFRB FGFR1 FLI1
6 neoplasm MP:0002006 9.8 ERG ETV4 FLI1 IGF1R KIT PTPRC
7 normal MP:0002873 9.61 DNTT ERG ETV1 FGFR1 KIT PDGFRB
8 renal/urinary system MP:0005367 9.17 ABCC6 ETV4 FGFR1 KIT PDGFRB PTPRC

Drugs & Therapeutics for Ewing Sarcoma

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009
2
Erbitux 17 45 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
3
Evista 17 45 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
4
Istodax 17 45 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
5
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
6
Treanda 17 45 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008

Drugs for Ewing Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 253)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
6
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
7
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
9
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
10
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
15
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
16
Zoledronic acid Approved Phase 3,Phase 1 118072-93-8 68740
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
19
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21
Treosulfan Investigational Phase 3 299-75-2 9296
22 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
23 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29
Cobalt Phase 3,Phase 2 7440-48-4 104729
30 Etoposide phosphate Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
32 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
33 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
36 Liver Extracts Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
38 topoisomerase I inhibitors Phase 3,Phase 1,Phase 2
39 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1
40 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
41 Protective Agents Phase 3,Phase 2,Phase 1
42 razoxane Phase 3,Phase 2
43 Adjuvants, Anesthesia Phase 3
44 Analgesics Phase 3,Phase 2,Phase 1
45 Analgesics, Opioid Phase 3
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Central Nervous System Depressants Phase 3,Phase 1
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 252)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
2 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
3 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
8 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
9 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
10 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;ifosfamide;etoposide;topotecan hydrochloride
11 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
12 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
14 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
15 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Unknown status NCT01696669 Phase 2 Chemotherapy
16 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
17 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
18 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
19 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
20 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed NCT01583543 Phase 2 Olaparib
21 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors Completed NCT00560235 Phase 1, Phase 2 CP-751,871
22 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
23 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
24 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2 Temozolomide;L9-NC
25 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed NCT00470275 Phase 2 cytarabine
26 Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
27 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
28 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
29 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
30 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
31 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
32 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
33 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2 exatecan mesylate
34 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed NCT00357396 Phase 2 busulfan;melphalan;thiotepa
35 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
36 Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor Completed NCT00062205 Phase 2 imatinib mesylate
37 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
38 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
39 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
40 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
41 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
42 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
43 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
44 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2 Vincristine;Cyclophosphamide;Adriamycin;Etoposide (VP-16);Cisplatin;Carboplatin;Melphalan;Ifosfamide;G-CSF (granulocyte-colony stimulating factor);Mesna
45 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2 plerixafor;plerixafor;plerixafor
46 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
47 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
48 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
49 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
50 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas Completed NCT00043979 Phase 2 F-18 Fluorodeoxyglucose;cyclophosphamide;cyclosporine;doxorubicin hydrochloride;etoposide;fludarabine phosphate;melphalan;prednisone;sirolimus;tacrolimus;vincristine sulfate;Filgrastim

Search NIH Clinical Center for Ewing Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: eye diseases

Genetic Tests for Ewing Sarcoma

Genetic tests related to Ewing Sarcoma:

# Genetic test Affiliating Genes
1 Ewing's Sarcoma 28 EWSR1
2 Abnormality of the Eye 28

Anatomical Context for Ewing Sarcoma

MalaCards organs/tissues related to Ewing Sarcoma:

38
Bone, Eye, Lung, Endothelial, T Cells, Kidney, Nk Cells

Publications for Ewing Sarcoma

Articles related to Ewing Sarcoma:

(show top 50) (show all 470)
# Title Authors Year
1
Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. ( 29425745 )
2018
2
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. ( 29412642 )
2018
3
The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling. ( 29386236 )
2018
4
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. ( 28868758 )
2018
5
Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. ( 29386915 )
2018
6
Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment. ( 29298256 )
2018
7
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( 29335623 )
2018
8
Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. ( 29382926 )
2018
9
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. ( 29358035 )
2018
10
Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma. ( 29434937 )
2018
11
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. ( 29416716 )
2018
12
Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. ( 29397557 )
2018
13
Intracranial Ewing sarcoma: four pediatric examples. ( 29285586 )
2018
14
Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. ( 29328472 )
2018
15
MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. ( 29263143 )
2018
16
Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax. ( 29431250 )
2018
17
Beclin-1 knockdown decreases proliferation, invasion and migration of Ewing sarcoma SK-ES-1 cells via inhibition of MMP-9. ( 29435061 )
2018
18
Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT. ( 28806254 )
2017
19
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. ( 28417551 )
2017
20
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. ( 28319067 )
2017
21
Pulmonary Nodule Size <5 mm Still Warrants Investigation in Patients With Osteosarcoma and Ewing Sarcoma. ( 28060128 )
2017
22
Microscopic Infiltration of Cryopreserved Ovarian Tissue in 2 Patients With Ewing Sarcoma. ( 28816797 )
2017
23
Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. ( 28062706 )
2017
24
Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. ( 28864350 )
2017
25
A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors. ( 28534008 )
2017
26
Rare presentation of Ewing sarcoma metastasis to the sella and suprasellar cistern. ( 27816880 )
2017
27
Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. ( 28060130 )
2017
28
Entering the Double Digits-Ewing Sarcoma In Adult Maxilla. ( 28472564 )
2017
29
Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. ( 28355116 )
2017
30
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
31
EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma. ( 27375017 )
2017
32
A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. ( 29263409 )
2017
33
CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. ( 28404587 )
2017
34
EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells. ( 28902354 )
2017
35
EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma. ( 28671673 )
2017
36
(18)F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. ( 28928879 )
2017
37
Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. ( 28507811 )
2017
38
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2017
39
Ewing sarcoma of the sternal manubrium: first report of a case in Australasia and review of the literature. ( 28419662 )
2017
40
Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. ( 28841702 )
2017
41
Inadvertently boarding a pirate ship: disease progression in a paediatric patient with relapsed metastatic Ewing sarcoma receiving treatment at a centre for alternative therapy in Mexico. ( 28062429 )
2017
42
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. ( 27918348 )
2017
43
Bone adaptation of a biologically reconstructed femur after Ewing sarcoma: Long-term morphological and densitometric evolution. ( 28447127 )
2017
44
ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma. ( 29270775 )
2017
45
Primary Ewing Sarcoma of the Mastoid: A Novel Case Mimicking Acute Mastoiditis. ( 29176463 )
2017
46
Second malignancies in Ewing sarcoma survivors. ( 28837218 )
2017
47
Outcome of resectable pediatric Ewing sarcoma of the ribs. ( 28462848 )
2017
48
Extra-skeletal Ewing sarcoma of the lumbosacral region in an adult pregnant patient: a case report. ( 28435928 )
2017
49
Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor. ( 28382842 )
2017
50
EWS-FLI1 Retargets BAF Chromatin Remodeling Complexes in Ewing Sarcoma. ( 28864478 )
2017

Variations for Ewing Sarcoma

ClinVar genetic disease variations for Ewing Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 VPS13B NM_017890.4(VPS13B): c.2591C> A (p.Ser864Ter) single nucleotide variant Pathogenic/Likely pathogenic rs140936527 GRCh37 Chromosome 8, 100286501: 100286501
2 RDH12 NM_152443.2(RDH12): c.806_810delCCCTG (p.Ala269Glyfs) deletion Pathogenic rs386834261 GRCh37 Chromosome 14, 68196055: 68196059
3 ABCC6 NM_001171.5(ABCC6): c.3389C> T (p.Thr1130Met) single nucleotide variant Pathogenic/Likely pathogenic rs63750459 GRCh37 Chromosome 16, 16256967: 16256967
4 CNGA3 NM_001298.2(CNGA3): c.1688G> A (p.Arg563His) single nucleotide variant Pathogenic/Likely pathogenic rs552069173 GRCh37 Chromosome 2, 99013321: 99013321
5 CNGB3 NM_019098.4(CNGB3): c.1285delT (p.Ser429Leufs) deletion Pathogenic/Likely pathogenic rs776896038 GRCh37 Chromosome 8, 87645015: 87645015
6 ABCC6 NM_001171.5(ABCC6): c.4104delC (p.Asp1368Glufs) deletion Pathogenic rs72664237 GRCh38 Chromosome 16, 16154732: 16154732
7 IMPG2 NM_016247.3(IMPG2): c.1680T> A (p.Tyr560Ter) single nucleotide variant Pathogenic rs758291149 GRCh37 Chromosome 3, 100963495: 100963495

Cosmic variations for Ewing Sarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 33

Copy number variations for Ewing Sarcoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13324 1 1 124300000 Deletion Ewing''s sarcoma
2 13741 1 1 27800000 Deletion Ewing''s sarcoma
3 16432 1 124300000 247249719 Gain Ewing''s sarcoma
4 16433 1 124300000 247249719 Gain Ewing''s sarcoma
5 16640 1 1286916 1536363 Loss Ewing''s sarcoma
6 17338 1 142400000 247249719 Gain Ewing''s sarcoma
7 17361 1 142565191 158296814 Gain AG1 Ewing''s sarcoma
8 20077 1 15300000 154800000 Gain Ewing''s sarcoma
9 20877 1 154978607 154979115 Gain HDGF Ewing''s sarcoma
10 21389 1 158408551 189951958 Gain FREB Ewing''s sarcoma
11 27410 1 208096981 208097464 Gain C1orf107 Ewing''s sarcoma
12 27922 1 215848737 215849264 Copy number GPATCH2 Ewing''s sarcoma
13 28256 1 220611046 220683633 Loss FBXO28 Ewing''s sarcoma
14 28623 1 224110806 224111244 Gain TMEM63A Ewing''s sarcoma
15 29204 1 228895774 228896323 Gain COG2 Ewing''s sarcoma
16 29247 1 229426179 229426672 Copy number C1orf131 Ewing''s sarcoma
17 29294 1 2300000 27800000 Deletion Ewing''s sarcoma
18 29735 1 234815741 234816376 Gain HEATR1 Ewing''s sarcoma
19 31804 1 3118000 5001000 Deletion Ewing''s sarcoma
20 31805 1 3118000 5001000 Deletion Ewing''s sarcoma
21 34220 1 53642491 53911866 Loss DMRTB1 Ewing''s sarcoma
22 35775 1 67181498 104009233 Loss SLC35D1 Ewing''s sarcoma
23 37996 1 9778925 10706826 Deletion APITD1 Ewing''s sarcoma
24 37997 1 9778925 10706826 Deletion CLSTN1 Ewing''s sarcoma
25 37998 1 9778925 10706826 Deletion CORT Ewing''s sarcoma
26 37999 1 9778925 10706826 Deletion CTNNBIP1 Ewing''s sarcoma
27 38000 1 9778925 10706826 Deletion DFFA Ewing''s sarcoma
28 38001 1 9778925 10706826 Deletion LZIC Ewing''s sarcoma
29 38002 1 9778925 10706826 Deletion NMNAT1 Ewing''s sarcoma
30 38003 1 9778925 10706826 Deletion PEX14 Ewing''s sarcoma
31 38004 1 9778925 10706826 Deletion PGD Ewing''s sarcoma
32 38005 1 9778925 10706826 Deletion RBP7 Ewing''s sarcoma
33 38141 10 1 135374737 Deletion Ewing''s sarcoma
34 41153 10 138206 135293404 Gain Ewing''s sarcoma
35 48491 11 1 52900000 Gain Ewing''s sarcoma
36 55430 11 52900000 134452384 Gain Ewing''s sarcoma
37 59789 11 777331 821974 Loss BM88 Ewing''s sarcoma
38 60445 11 86456481 127953177 Loss Ewing''s sarcoma
39 61420 12 1 132349534 Gain Ewing''s sarcoma
40 61533 12 1 35400000 Gain Ewing''s sarcoma
41 62737 12 111075038 111075556 Gain TRAFD1 Ewing''s sarcoma
42 63302 12 116955326 116955682 Copy number WSB2 Ewing''s sarcoma
43 64487 12 12873623 12874134 Gain DDX47 Ewing''s sarcoma
44 65323 12 1570852 1571348 Copy number FBXL14 Ewing''s sarcoma
45 66228 12 2670999 2671234 Deletion CACNA1C Ewing''s sarcoma
46 67041 12 35400000 132349534 Gain Ewing''s sarcoma
47 67472 12 41121456 41121979 Gain PPHLN1 Ewing''s sarcoma
48 68463 12 49967 52715434 Gain IQSEC3 Ewing''s sarcoma
49 68787 12 51501640 51502010 Copy number KRT79 Ewing''s sarcoma
50 69068 12 52981304 57130106 Gain Ewing''s sarcoma

Expression for Ewing Sarcoma

Search GEO for disease gene expression data for Ewing Sarcoma.

Pathways for Ewing Sarcoma

Pathways related to Ewing Sarcoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Ewing Sarcoma

Biological processes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.78 FGFR1 KIT NCAM1 PDGFRB
2 transcription by RNA polymerase II GO:0006366 9.73 ERG ETV1 ETV4 FLI1 POU5F1 WT1
3 male gonad development GO:0008584 9.7 KIT PDGFRB WT1
4 phosphatidylinositol phosphorylation GO:0046854 9.67 FGFR1 KIT PDGFRB
5 protein autophosphorylation GO:0046777 9.67 FGFR1 IGF1R KIT PDGFRB
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.63 FGFR1 KIT PDGFRB
7 peptidyl-tyrosine phosphorylation GO:0018108 9.62 FGFR1 IGF1R KIT PDGFRB
8 positive regulation of MAP kinase activity GO:0043406 9.58 FGFR1 KIT PDGFRB
9 megakaryocyte development GO:0035855 9.51 FLI1 KIT
10 metanephric mesenchyme development GO:0072075 9.43 PDGFRB WT1
11 metanephric S-shaped body morphogenesis GO:0072284 9.16 PDGFRB WT1
12 phosphatidylinositol-mediated signaling GO:0048015 9.13 FGFR1 IGF1R PDGFRB
13 positive regulation of phospholipase C activity GO:0010863 8.8 FGFR1 KIT PDGFRB

Molecular functions related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.73 ERG ETV1 ETV4 FLI1 POU5F1 WT1
2 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.67 ERG ETV4 FLI1 POU5F1
3 protein tyrosine kinase activity GO:0004713 9.62 FGFR1 IGF1R KIT PDGFRB
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 FGFR1 KIT PDGFRB
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.55 ERG ETV1 ETV4 FLI1 WT1
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 FGFR1 KIT NCAM1 PDGFRB
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 FGFR1 IGF1R KIT PDGFRB
8 protein binding GO:0005515 10.36 CD99 DNTT ENO2 ERG ETV1 ETV4

Sources for Ewing Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....